CROWN: long-acting cabotegravir + rilpivirine versus standard of care in viremic people with HIV-1 and suboptimal response to oral ART

Phase 3, randomised, open-label trial in human immunodeficiency virus infection (HIV) comparing Injectable cabotegravir + rilpivirine long-acting with Standard of care control (2 arms). Primary endpoint: Virologic response at Month 6. Planned start Dec 2024; status: authorised.